In immunocompetent murine models of lymphoma and neuroblastoma, IT rotavirus therapy demonstrated that it can overcome immune checkpoint inhibitor resistance.
Rechallenge with dabrafenib plus trametinib demonstrated antitumor activity in patients who had previously progressed on BRAF inhibitor therapy.
Adding the anti-malaria drug chloroquine to standard therapies may help combat resistance to therapy and also resensitize glioblastoma patients to targeted treatments that had previously stopped working.
New Understanding of Mechanisms Revealed in Development of Breast Cancer and Resistance to TreatmentJanuary 25, 2017
Researchers explore the biologic influences of breast cancer development and resistance to treatment.
A recent study undertaken sought to examine the effects of chemotherapy on bladder cancer cells and possible connections to later treatment resistance.
Danish researchers identified a microRNA shown to predict whether a patient with colorectal cancer would be resistant to oxaliplatin treatment, a discovery that holds promise of improving both current treatment options and development of future treatment strategies.
Dab2 is an endocytic adaptor and tumor suppressor whose expression occurs during the epithelial-mesenchymal transition, which is mediated by TGF-beta. This study sought to understand how Dab2 regulates apoptosis.
A new perspective on chemotherapy resistance in ovarian cancer may be a step toward overcoming that resistance. Fibroblasts block chemotherapy, leading to chemotherapy resistance; however, immune system T cells can reverse that resistance.
The second-generation hsp90 inhibitor onalespib may be beneficial for men with prostate cancer that no longer responds to androgen deprivation therapy
Researchers have pinpointed the evolutionary process cancer cells use to resist the drug LOXO-101.
The expression of the PAX3 and MITF genes in melanoma can cause early, nonmutational, reversible drug resistance; tissues that express these genes can then later develop mutational, irreversible drug resistance. The HIV drug nelfinavir can prevent this resistance.
Cyclin D1/CDK4 inhibitor treatment overcame resistance to targeted therapy in transgenic mouse models, cell cultures, and human tissue samples of HER2-positive breast cancer.
New study findings presented at SABCS 2015 suggest that BRCAT431 promotes tamoxifen resistance, thereby increasing the clinical risk of recurrence and metastases in breast cancer.
Scientists have discovered how to sensitize drug-resistant human glioblastoma cells to chemotherapy.
Scientists developed a highly sensitive blood test that indicates when breast cancers become resistant to standard hormone treatment. In addition, the test results can be used to guide further treatment.
Researchers discovered a new explanation for why women with ER+ breast cancer develop resistance to hormone treatment, and a potential new approach that may overcome the problem.
High-grade serous ovarian cancer often responds well to the chemotherapy drug carboplatin, but researchers are investigating why it frequently returns after treatment.
Researchers urge for new targeted inhibitors and combinations to combat tumors' constant and varied molecular adaptation.
New research indicate that malfunctioning genes are only partly to blame for why treatment that was effective ultimately fails in many patients with the most common form of non-Hodgkin lymphoma.
Two experimental medications target mutation that fuels treatment resistance in lung cancer.
Experiments in mice suggest that elevated blood levels of the fatty acid derived from fish oil may induce resistance to chemotherapy.
Investigators have discovered one way in which melanoma becomes resistant to a particular form of targeted therapy, a discovery that may lead to a new melanoma target or prompt new designs for treatment.
A previously unrecognized action as a potent inhibitor of the dominant mutation that confers drug resistance to all well-tolerated treatments in patients with certain leukemia types has been found in Axitinib.
Researchers have discovered that ERBB4 (also known as HER4) is a driver protein in ERBB2-positive tumors that have developed resistance to first- or second-line treatments.
Current research has identified a signaling pathway responsible for the generation of slowly proliferating cancer cells that are hard to eradicate via current treatments.
Researchers have identified two genes that appear to be simultaneously overexpressed in aggressive prostate cancers resistant to the androgen-targeted treatments enzalutamide and abiraterone acetate.
Researchers have uncovered how melanoma becomes resistant to a promising new drug combination utilizing BRAF+MEK inhibitors after an initial period of tumor shrinkage.
The researchers have mapped the steps used by cells of melanoma, breast cancer, and the blood cancer myelofibrosis to become resistant to drugs, allowing for better success in blocking these pathways and further enabling therapies.
Examination of the DNA of a thyroid cancer survivor has revealed details about resistance to the drug everolimus, according to researchers.
IMPRESS trial fails to find benefit from more tyrosine kinase inhibitor (TKI) treatment after resistance developsOctober 17, 2014
Patients with lung cancer that have developed resistance to the drug gefitinib experience no statistically significant improvement in progression-free survival when continued use of the drug with chemotherapy is utilized.
Sign Up for Free e-newsletters
- Triplet Regimen Found Most Effective for Relapsed/Refractory Multiple Myeloma
- Integrating Preoperative Oral Care Into Cancer Treatment Plans
- Current Status and Dilemma of Second-line Treatment in Advanced Pancreatic Cancer: Is There a Silver Lining?
- American Association for Cancer Research Releases Its 2018 Annual Report
- Pulmonary Toxicity Increased in Pediatric Hodgkin Lymphoma Treated With Brentuximab Vedotin
- Benefit of Chemotherapy for Breast Cancer Observed With Midrange Gene Assay Score
- Antioxidant Interaction With Cancer Therapy
- Young Survivors of Breast Cancer Report Sexual Quality of Life Declines After Treatment
- Myeloablative Conditioning Effective in AML Secondary to MDS/MPN Prior to Allogeneic HCT
- Insurance Status Influences Overall Survival in Follicular Lymphoma
- Skin Cancer Screening: Are They Effective?
- Metronidazole, Vancomycin Recommended for C Difficile in Pediatric Oncology, HSCT
- CDC: HPV Vaccination Rates on the Rise Among Adolescents
- High-Dose vs Standard-Dose Flu Vaccine in Elderly Receiving Chemotherapy
- FDA Grants Approval to Novel Treatment for Hairy Cell Leukemia
Regimen and Drug Listings
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
|Head and Neck Cancer||Regimens||Drugs|